Melanoma antigen preferentially expressed in tumors
Registration of APIs CMC information required for an IND
IND and NDA support Drug master files (DMF) filing
Synonyms/Alias | Melanoma antigen preferentially expressed in tumors (100-108) |
Sequence | VLDGLDVLL |
Areas of Interest | Antigen-presenting Cells; Cancer Research |
Source# | Homo sapiens (human) |
Epitope | 100-108 |
Restricting HLA | HLA-A2 |
References | Kessler; J Exp Med 2001 |
1. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis
5. Cationic cell-penetrating peptides are potent furin inhibitors
Required fields are marked with *
×Required fields are marked with *
×If you have any peptide synthesis requirement in mind, please do not hesitate to contact us. We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com